Skip to main content
OpenTrials
Completed

NCT Number: NCT06200545

Improving HIV Prevention Among Heterosexual Men Seeking STI Services in Malawi

To evaluate the potential benefit(s), acceptability, and associated costs of a systems navigator-delivered HIV prevention intervention in promoting and supporting persistent use of evidence-based HIV pre-exposure prophylaxis (PrEP) among heterosexual men receiving care for sexually transmitted infections (STIs) in Lilongwe, Malawi.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Infection Behavior Blood-Borne Infections Communicable Diseases Disease Attributes Genital Diseases HIV Infections Heterosexuality Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pre-exposure Prophylaxis RNA Virus Infections Retroviridae Infections Sexual Behavior Sexuality Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Infections Systems Navigation Urogenital Diseases Virus Diseases

Age range

15 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Malawi CRS

Lilongwe, Malawi

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult and adolescent men who meet all of the following criteria are eligible for inclusion in this study as a participant initiating PrEP:
  • Age ≥18 years, or age 15-17 (with assent and parent/guardian consent)
  • Able to provide informed consent
  • No plans to move outside study area for at least 26 weeks after study enrollment
  • Willing to provide contact/locator information, including phone number, to facilitate tracing
  • Willing to participate in study activities, including specimen collection
  • Willing to participate in study activities, including systems navigation, counseling, and point of contact STI testing
  • Sought STI clinic services within 7 days of enrollment
  • Initiated on PrEP at STI clinic within 7 days of enrollment
  • Reports at least one female sex partner in the 6 months prior to enrollment
  • Self-identifies as heterosexual
  • Individuals who meet all of the following criteria are eligible for inclusion in this study as other key stakeholders:
  • Age ≥18 years at the enrollment visit
  • Able to provide informed consent
  • Involved in provision of clinical service navigation, systems navigation, STI or HIV care or prevention (including clinic management or oversight), or development of HIV prevention policy or programs at local or national level

Exclusion criteria

  • Adult and adolescent men who meet any of the following criteria are ineligible for inclusion in this study as a participant initiating PrEP:
  • Appearance of psychological disturbance or cognitive impairment that would limit the ability to understand study procedures, as determined by the investigators
  • Any other condition that, in the opinion of the investigators, would make participation in the study unsafe, or otherwise interfere with the conduct of the study
  • Current participation in any HIV prevention study or other study considered to interfere the interpretation of study outcomes.
  • Individuals who meet any of the following criteria are ineligible for inclusion in this study as other key stakeholder:
  • Appearance of psychological disturbance or cognitive impairment that would limit the ability to understand study procedures, as determined by the investigators
  • Any other condition that, in the opinion of the investigators, would make participation in the study unsafe, or otherwise interfere with the study activities

Treatment and study plan

PrEP eligibility assessment

Other

PrEP eligibility assessment

Rapid HIV antibody testing prior to provision and/or refill of PrEP

Diagnostic Test

Rapid HIV antibody testing prior to provision and/or refill of PrEP

PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines

Other

PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines

Evaluation of barriers and facilitators to ongoing PrEP use

Behavioral

Evaluation of barriers and facilitators to ongoing PrEP use

Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement

Other

Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement

Tracing for any missed PrEP visits

Other

Tracing for any missed PrEP visits

Offering a PrEP "restart" kit for men who choose to discontinue PrEP during the follow-up period

Other

Offering a PrEP "restart" kit for men who choose to discontinue PrEP during the follow-up period

Primary outcomes

  1. To assess the effect of a systems-navigator facilitated HIV prevention package on PrEP persistence among heterosexual men seeking STI clinical services in Lilongwe, Malawi

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed: Persistent PrEP use across all three modalities (LAI, daily oral, or event-driven PrEP), where persistence is defined as adherence to any PrEP modality through 26 weeks, comparing proportions in intervention and control arm participants.

    LAI: Receive on-time injections (+/- 7-day window for the first injection and 14-day window thereafter)

  2. To assess the effect of a systems-navigator facilitated HIV prevention package on PrEP persistence among heterosexual men seeking STI clinical services in Lilongwe, Malawi

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed: Persistent PrEP use across all three modalities (LAI, daily oral, or event-driven PrEP), where persistence is defined as adherence to any PrEP modality through 26 weeks, comparing proportions in intervention and control arm participants.

    Daily Oral: Have protective PrEP concentration detected at designated study follow-up visits, based on intraerythrocytic Tenofovir-diphosphate collected as dried blood spot; Tenofovir-diphosphate concentrations associated with ≥4 doses/week will be classified as adherent.

  3. To assess the effect of a systems-navigator facilitated HIV prevention package on PrEP persistence among heterosexual men seeking STI clinical services in Lilongwe, Malawi

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed: Persistent PrEP use across all three modalities (LAI, daily oral, or event-driven PrEP), where persistence is defined as adherence to any PrEP modality through 26 weeks, comparing proportions in intervention and control arm participants.

    Event-driven: Self-reported PrEP adherence (2+1+1), in the past 30 days, assessed through self-report of PrEP use and sex acts at study follow-up visits.

  4. To assess the effect of a systems-navigator facilitated HIV prevention package on PrEP persistence among heterosexual men seeking STI clinical services in Lilongwe, Malawi

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed: Persistent PrEP use across all three modalities (LAI, daily oral, or event-driven PrEP), where persistence is defined as adherence to any PrEP modality through 26 weeks, comparing proportions in intervention and control arm participants.

    Event-driven: Self-reported PrEP adherence (2+1+1), in the past 30 days, assessed through intraerythrocytic Tenofovir-diphosphate concentrations.

  5. To assess acceptability and barriers of implementing a systems-navigator delivered HIV prevention package among key stakeholders in the clinic and heterosexual men initiating PrEP at STI clinics

    Time frame: 7 days

    Consistent with this primary study objective, the following endpoint will be assessed among participants in the intervention arm only:

    Engagement with system navigators: Proportion of intervention arm participants engaged by systems navigator within 7-days of enrollment visit (defined as any contact, i.e. text exchange, in-person communication)

  6. To assess acceptability and barriers of implementing a systems-navigator delivered HIV prevention package among key stakeholders in the clinic and heterosexual men initiating PrEP at STI clinics

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed among participants in the intervention arm only:

    Engagement with system navigators: Proportion of intervention arm participants engaged by systems navigators at least once after the initial engagement during the first 26 weeks following initiation of PrEP.

  7. To assess acceptability and barriers of implementing a systems-navigator delivered HIV prevention package among key stakeholders in the clinic and heterosexual men initiating PrEP at STI clinics

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed among participants in the intervention arm only:

    Engagement with system navigators: Proportion of intervention arm participants with attempted engagement by systems navigators at least once after the initial engagement during the first 26 weeks following initiation of PrEP.

  8. To assess acceptability and barriers of implementing a systems-navigator delivered HIV prevention package among key stakeholders in the clinic and heterosexual men initiating PrEP at STI clinics

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed among participants in the intervention arm only:

    Engagement with system navigators: Mean (standard error) number of contacts (text, telephone call, home visit, other) with intervention arm participants made with systems navigators (mean contacts per participant) during first 26 weeks following initiation of PrEP.

  9. To assess acceptability and barriers of implementing a systems-navigator delivered HIV prevention package among key stakeholders in the clinic and heterosexual men initiating PrEP at STI clinics

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed among participants in the intervention arm only:

    Uptake of self-test/pill pack ("re-start" kit) among those to whom it is distributed (through end of study participation): Proportion who self-report use of HIV self-test

  10. To assess acceptability and barriers of implementing a systems-navigator delivered HIV prevention package among key stakeholders in the clinic and heterosexual men initiating PrEP at STI clinics

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed among participants in the intervention arm only:

    Uptake of self-test/pill pack ("re-start" kit) among those to whom it is distributed (through end of study participation): Proportion who self-report use of PrEP pill pack

  11. To assess acceptability and barriers of implementing a systems-navigator delivered HIV prevention package among key stakeholders in the clinic and heterosexual men initiating PrEP at STI clinics

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed among participants in the intervention arm only:

    Uptake of self-test/pill pack ("re-start" kit) among those to whom it is distributed (through end of study participation): Proportion who self-report use of HIV self-test in conjunction with/prior to initiation of PrEP pill pack

  12. To assess acceptability and barriers of implementing a systems-navigator delivered HIV prevention package among key stakeholders in the clinic and heterosexual men initiating PrEP at STI clinics

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed among participants in the intervention arm only:

    Acceptability and barriers among key stakeholders, including participants enrolled as seronegative PrEP initiators and other key stakeholders: Acceptability based on quantitative surveys (participants enrolled as seronegative PrEP initiators only)

  13. To assess acceptability and barriers of implementing a systems-navigator delivered HIV prevention package among key stakeholders in the clinic and heterosexual men initiating PrEP at STI clinics

    Time frame: 26 weeks

    Consistent with this primary study objective, the following endpoint will be assessed among participants in the intervention arm only:

    Acceptability and barriers among key stakeholders, including participants enrolled as seronegative PrEP initiators and other key stakeholders: Perceived facilitators and barriers to implementation of the intervention will be assessed through individual semi-structured interviews.

Secondary outcomes

  1. To assess the feasibility of a future randomized controlled trial

    Time frame: 52 weeks

    Consistent with this secondary study objective, the following endpoint will be assessed, considering all enrolled HIV seronegative participants:

    Calendar time to enroll 200 participants

  2. To assess the feasibility of a future randomized controlled trial

    Time frame: 52 weeks

    Consistent with this secondary study objective, the following endpoint will be assessed, considering all enrolled HIV seronegative participants:

    Proportion of participants retained at each [eligible] study visit

  3. To assess the feasibility of a future randomized controlled trial

    Time frame: 52 weeks

    Consistent with this secondary study objective, the following endpoint will be assessed, considering all enrolled HIV seronegative participants:

    Complete all study visits through 26 weeks, 39 weeks, and 52 weeks (among participants eligible for longer follow-up)

  4. To assess the feasibility of a future randomized controlled trial

    Time frame: 52 weeks

    Consistent with this secondary study objective, the following endpoint will be assessed, considering all enrolled HIV seronegative participants:

    Proportion of PrEP visits on the same day as study visits, by PrEP modality

  5. To assess the feasibility of a future randomized controlled trial

    Time frame: 52 weeks

    Consistent with this secondary study objective, the following endpoint will be assessed, considering all enrolled HIV seronegative participants:

    Proportion of participants completing 30-day Timeline Follow-back at quarterly study visits

  6. To assess the feasibility of a future randomized controlled trial

    Time frame: 52 weeks

    Consistent with this secondary study objective, the following endpoint will be assessed, considering all enrolled HIV seronegative participants:

    Time to complete each study visit

  7. To assess the feasibility of a future randomized controlled trial

    Time frame: 52 weeks

    Consistent with this secondary study objective, the following endpoint will be assessed, considering all enrolled HIV seronegative participants:

    Additional time (at PrEP visits) engaging with systems navigators

Sponsors and collaborators

Lead sponsor

HIV Prevention Trials Network

Network

Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Official study title

Improving HIV Prevention Among Heterosexual Men Seeking STI Services in Malawi: Examining the Benefits, Acceptability, and Associated Costs of a Systems-navigator-delivered Integrated Prevention Package

Acronym: NJIRA

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 11, 2024
Registry last updated
Dec 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.